Imaging non-motor aspects of Parkinson's disease

Progress in Brain Research

Volumn 184, Issue C, 2010, Pages 205-218

  Brooks, David J ^a   Pavese, Nicola ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Dementia; Depression; Fatigue Autonomic; Parkinson; Sleep

Indexed keywords

AMYLOID BETA PROTEIN; GLUCOSE;

ALZHEIMER DISEASE; BOOK; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DOPAMINERGIC ACTIVITY; DYSAUTONOMIA; FATIGUE; GLUCOSE METABOLISM; HUMAN; MONOAMINERGIC SYSTEM; NEUROIMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SMELLING;

EID: 77957224463     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(10)84011-7     Document Type: Chapter

References (51)

1. Aarsland D., Perry R., Brown A., Larsen J.P., Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005, 58(5):773-776.
2. Abe K., Takanashi M., Yanagihara T. Fatigue in patients with Parkinson's disease. Behav Neurol 2000, 12(3):103-106.
3. Agid Y., Javoy-Agid F., Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. Movement Disorders 2 1987, 166-230. Butterworths, London. C.D. Marsden, S. Fahn (Eds.).
4. Asahina M., Suhara T., Shinotoh H., Inoue O., Suzuki K., Hattori T. Brain muscarinic recptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J.Neurol.Neurosurg.Psychiat. 1998, 65:155-163.
5. Berding G., Brucke T., Odin P., Brooks D.J., Kolbe H., Gielow P., et al. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy. Nuklearmedizin 2003, 42(1):31-38.
6. Bohnen N.I., Gedela S., Herath P., Constantine G.M., Moore R.Y. Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. Neurosci Lett 2008, 447(1):12-16.
7. Bohnen N.I., Kaufer D.I., Hendrickson R., Ivanco L.S., Lopresti B.J., Constantine G.M., et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol. 2005.
8. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004, 318(1):121-134.
9. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001, 11(1):351-355.
10. Burn D.J. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002, 17(3):445-454.
11. Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006, 5(1):235-245.
12. Colloby S.J., Pakrasi S., Firbank M.J., Perry E.K., Piggott M.A., Owens J., et al. In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. Neuroimage 2006, 33(2):423-429.
13. Doder M., Rabiner E.A., Turjanski N., Lees A.J., Brooks D.J. Brain serotonin HT1A receptors in Parkinson's disease with and without depression measured by positron emission tomography and 11C-WAY100635. Movement Disorders 2000, 15(Supp 3):213.
14. Edison P., Archer H., Hinz R., Hammers A., Tai Y.F., Pavese N., et al. Amyloid deposition and metabolic dysfunction in Alzheimer's disease and mild cognitive impairment: An 11C-PIB and 18FDG PET study. Neurology 2006, 66(5):A249-A250.
15. Edison P., Rowe C.C., Rinne J.O., Ng S., Ahmed I., Kemppainen N., et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008, 79(12):1331-1338.
16. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003, 2(4):229-237.
17. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
18. Gomperts S.N., Rentz D.M., Moran E., Becker J.A., Locascio J.J., Klunk W.E., et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008, 71(12):903-910.
19. Guttman M., Boileau I., Warsh J., Saint-Cyr J.A., Ginovart N., McCluskey T., et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 2007, 14(5):523-528.
20. Guttman M., Burkholder J., Kish S.J., Hussey D., Wilson A., DaSilva J., et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: Implications for the symptomatic threshold. Neurology 1997, 48:1578-1583.
21. Haehner A., Hummel T., Hummel C., Sommer U., Junghanns S., Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 2007, 22(6):839-842.
22. Hagell P., Brundin L. Towards an understanding of fatigue in Parkinson disease. J Neurol Neurosurg Psychiatry 2009, 80(5):489-492.
23. Happe S., Baier P.C., Helmschmied K., Meller J., Tatsch K., Paulus W. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. J Neurol 2007, 254(8):1037-1043.
24. Hely M.A., Reid W.G., Adena M.A., Halliday G.M., Morris J.G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008, 23(6):837-844.
25. Hilker R., Razai N., Ghaemi M., Weisenbach S., Rudolf J., Szelies B., et al. [18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease. Clin Neurol Neurosurg 2003, 105(4):262-269.
26. Hilker R., Thomas A.V., Klein J.C., Weisenbach S., Kalbe E., Burghaus L., et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005, 65(11):1716-1722.
27. Hitten J.J., van Hoogland G., van der Velde E.A., et al. Diurnal effects of motor activity and fatigue in Parkinson's disease. J Neurol Neurosurg Psychiatry 1993, 56:874-877.
28. Hoffman J.M., Welsh-Bohmer K.A., Hanson M., Crain B., Hulette C., Earl N., et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000, 41(11):1920-1928.
29. Au M.T.M., Taylor-Robinson S.D., Chaudhuri K.R., Bell J.D., Labb C., Cunningham V.J., et al. Cortical dysfunction in non-demented Parkinson's disease patients: A combined 31Phosphorus MRS and 18FDG PET study. Brain 2000, 123:340-352.
30. Ito K., Nagano-Saito A., Kato T., Arahata Y., Nakamura A., Kawasumi Y., et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002, 125(Pt 6):1358-1365.
31. Kalaitzakis M.E., Graeber M.B., Gentleman S.M., Pearce R.K. Controversies over the staging of alpha-synuclein pathology in Parkinson's disease. Acta Neuropathol 2008, 116(1):125-128. author reply 129-131.
32. Karlsen K., Larsen J.P., Tandberg E., Jorgensen K. Fatigue in patients with Parkinson's disease. Mov Disord 1999, 14(2):237-241.
33. Kim S.E., Choi J.Y., Choe Y.S., Choi Y., Lee W.Y. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med 2003, 44(6):870-876.
34. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55(3):306-319.
35. Kuhl D.E., Minoshima S., Fessler J.A., Frey K.A., Foster N.L., Ficaro E.P., et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996, 40(3):399-410.
36. Maetzler W., Liepelt I., Reimold M., Reischl G., Solbach C., Becker C., et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009, 34(1):107-112.
37. Mayberg H., Starkstein S., Preziosi S., Bolduc P., Robinson R., Sadzot B., et al. Frontal lobe hypometabolism is associated with depression in Parkinson's disease. Neurology. 1989, 39(suppl):274.
38. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65(12):1863-1872.
39. O'Brien J.T., McKeith I.G., Walker Z., Tatsch K., Booij J., Darcourt J., et al. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 2009, 194(1):34-39.
40. Oka H., Yoshioka M., Onouchi K., Morita M., Mochio S., Suzuki M., et al. Characteristics of orthostatic hypotension in Parkinson's disease. Brain 2007, 130(Pt 9):2425-2432.
41. Remy P., Doder M., Lees A.J., Turjanski N., Brooks D.J. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128:1314-1322.
42. Rye D.B., Bliwise D.L., Dihenia B., Gurecki P. Daytime sleepiness in Parkinson's disease. Journal of Sleep Research 2000, 9(1):63-69.
43. Sawada H., Oeda T., Yamamoto K., Kitagawa N., Mizuta E., Hosokawa R., et al. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol 2009, 16(2):174-182.
44. Scherfler C., Schocke M.F., Seppi K., Esterhammer R., Brenneis C., Jaschke W., et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain 2006, 129(Pt 2):538-542.
45. Schifitto G., Friedman J.H., Oakes D., Shulman L., Comella C.L., Marek K., et al. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology 2008, 71(7):481-485.
46. Siderowf A., Newberg A., Chou K.L., Lloyd M., Colcher A., Hurtig H.I., et al. [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 2005, 64(10):1716-1720.
47. Walker Z., Costa D.C., Walker R.W., Shaw K., Gacinovic S., Stevens T., et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002, 73(2):134-140.
48. Walker Z., Jaros E., Walker R.W., Lee L., Costa D.C., Livingston G., et al. Dementia with lewy bodies: A comparison of clinical diagnosis, FP-CIT SPECT imaging and autopsy. J Neurol Neurosurg Psychiatry 2007, 78:1176-1181.
49. Weintraub D., Newberg A.B., Cary M.S., Siderowf A.D., Moberg P.J., Kleiner-Fisman G., et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med 2005, 46(2):227-232.
50. Yamamoto S., Ouchi Y., Onoe H., Yoshikawa E., Tsukada H., Takahashi H., et al. Reduction of serotonin transporters of patients with chronic fatigue syndrome. Neuroreport 2004, 15(17):2571-2574.
51. Yong S.W., Yoon J.K., An Y.S., Lee P.H. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 2007, 14(12):1357-1362.